美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Baillie Gifford International Alpha ETF

25.23

+0.01060.04%

成交量：8

成交额：201

市值：3.28亿

市盈率：- -

高：25.23

开：25.22

低：25.23

收：25.22

52周最高：25.97

52周最低：23.97

股本：1,301.20万

流通股本：1,301.20万

量比：0.00

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。

诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。

诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%

华尔街见闻

诺和诺德：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组

诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。

诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。

诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。

诺和诺德首席战略官表示，如果合适的机会出现，我们并不排除在肥胖领域进行收购。

诺和诺德首席科学官表示，公司希望同时将口服和皮下注射剂型的Zenagamtide推向市场。

诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”

诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”

诺和诺德首席执行官称，公司资产负债表可支撑更大规模交易。

朗格表示，诺和诺德同时在疼痛与成瘾领域探索新方向。

注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉

注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉

诺和诺德首席科学官：我们预计截至今年年底将至少有五款口服候选药物处于临床开发阶段。

诺和诺德首席执行官：到2030年，我们将为全球超过6000万患者提供服务。

诺和诺德首席执行官：到2030年，我们将为全球逾6000万患者提供服务。

诺和诺德CEO表示，将在失去独家专利权之前，就推出新款糖尿病和肥胖症创新药物。

诺和诺德首席执行官：我们将在专利独占期到期前推出下一拨糖尿病与肥胖症创新产品。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BGIA/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BGIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","market":"US","secType":"STK","nameCN":"Baillie Gifford International Alpha ETF","latestPrice":25.2294,"timestamp":1791921600000,"preClose":25.2188,"halted":0,"volume":8,"delay":0,"changeRate":0.00042032134756596714,"floatShares":13012033,"shares":13012033,"eps":0,"marketStatus":"未开盘","change":0.0106,"latestTime":"10-13 16:00:00 EDT","open":25.2188,"high":25.2294,"low":25.2294,"amount":201,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":25.2188,"bidAskSpread":0,"volumeRatio":0.002641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","floatShares":13012033,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.002641,"shares":13012033,"dividePrice":0,"high":25.2294,"amplitude":0,"preClose":25.2188,"low":25.2294,"week52Low":23.9707,"pbRate":"--","week52High":25.97,"institutionHeld":0,"latestPrice":25.2294,"eps":0,"divideRate":0,"volume":8,"delay":0,"ttmEps":0,"open":25.2188,"prevYearClose":25.2,"prevWeekClose":25.3417,"prevMonthClose":24.9683,"prevQuarterClose":24.9683,"fiveDayClose":25.4651,"twentyDayClose":24.9961,"sixtyDayClose":24.2745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BGIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BGIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BGIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BGIA\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669163293","title":"诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163293","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163293?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:17","pubTimestamp":1789993070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669716862","title":"诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669716862","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669716862?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:30","pubTimestamp":1789990240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669723157","title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669723157","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669723157?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:02","pubTimestamp":1789988564,"startTime":"0","endTime":"0","summary":"诺和诺德公布旗下减重药CagriSema最新临床数据：在与礼来替尔泊肽的直接比较中，CagriSema平均减重12.4%，高于替尔泊肽的9.1%；另一项试验中减重达21%。目前该药已提交FDA审批，预计今年第四季度迎来结果。","market":"nz","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3782221","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BGIA","NVO","NVOC","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157581","title":"诺和诺德 ：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157581?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:27","pubTimestamp":1789986423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669575841","title":"诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669575841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669575841?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157322","title":"诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157322?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715737","title":"诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669715737?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:24","pubTimestamp":1789986281,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669522321","title":"诺和诺德首席战略官表示，如果合适的机会出现，我们并不排除在肥胖领域进行收购。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669522321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669522321?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:12","pubTimestamp":1789985535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152912","title":"诺和诺德首席科学官表示，公司希望同时将口服和皮下注射剂型的Zenagamtide推向市场。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152912","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669152912?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985039,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151761","title":"诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151761","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151761?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:24","pubTimestamp":1789982648,"startTime":"0","endTime":"0","summary":"诺和诺德美股ADR在周一美股盘前也大幅走弱，一度大跌超过7%。诺和诺德最新的230亿美元目标销售额似乎不及市场预期。尽管诺和诺德率先推出了新一代强效药物，使肥胖症变得更易治疗，但它仍落后于礼来。诺和诺德此前表示，今年整体利润以及营收最多可能下降6%。诺和诺德此次提出的新药蓝图，体现了其通过产品迭代争取下一轮增长的意图。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151751","title":"诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151751","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151751?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:24","pubTimestamp":1789982648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315117","title":"诺和诺德首席执行官称，公司资产负债表可支撑更大规模交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315117","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315117?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:18","pubTimestamp":1789982321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","BGIA","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151679","title":"朗格表示，诺和诺德同时在疼痛与成瘾领域探索新方向。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151679?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:11","pubTimestamp":1789981896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669759159","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669759159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669759159?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:54","pubTimestamp":1789980888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CURE","MEDI","PINK","PJP","TRUH","NVOH","NVOC","NVOX","THNR","BGIA","NBDS","FHLC","XLVI","IYH","RSPH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669590351","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669590351","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669590351?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:53","pubTimestamp":1789980780,"startTime":"0","endTime":"0","summary":"一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变（简称NAION）。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880057798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880057798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CURE","NVOH","RSPH","PINK","IYH","NVOX","TRUH","FHLC","BGIA","XLVI","NBDS","NVOC","PJP","FXH","MEDI","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159114","title":"诺和诺德首席科学官：我们预计截至今年年底将至少有五款口服候选药物处于临床开发阶段。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159114?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:47","pubTimestamp":1789980446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669598841","title":"诺和诺德首席执行官：到2030年，我们将为全球超过6000万患者提供服务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669598841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669598841?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:34","pubTimestamp":1789979685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159834","title":"诺和诺德首席执行官：到2030年，我们将为全球逾6000万患者提供服务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159834?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:34","pubTimestamp":1789979685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156777","title":"诺和诺德CEO表示，将在失去独家专利权之前，就推出新款糖尿病和肥胖症创新药物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156777","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156777?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:32","pubTimestamp":1789979564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LNGR","IBBQ","MEDX","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156749","title":"诺和诺德首席执行官：我们将在专利独占期到期前推出下一拨糖尿病与肥胖症创新产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156749?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:30","pubTimestamp":1789979416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":199,"code":"91000000","status":"200"}]}}